MKI67 and breast cancer: The so-called classic biomarkers of breast cancer (ER, PR and androgen (AR) hormone receptors, the HER2 receptor, and the Ki-67 cell proliferation marker) were the first ones to be studied and standardized and remain pillars of the clinical management of this disease, despite the emergence of new molecular candidates.